# Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

> **NCT00817531** · PHASE2 · TERMINATED · sponsor: **Baylor Breast Care Center** · enrollment: 22 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00817531
- **Lead sponsor:** Baylor Breast Care Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** terminated due to futility after interim analysis
- **Last updated:** 2012-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00817531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00817531, "Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00817531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*